Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis
Background The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) is a novel questionnaire of global functioning for patients with axial spondyloarthritis (SpA).Objective The objective was to assess the construct validity, discriminatory ability and responsiveness of ASAS H...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/4/e004948.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841536277974876160 |
|---|---|
| author | Merete Lund Hetland Inge Juul Sørensen Mikkel Østergaard Mikael Boesen Susanne Juhl Pedersen Sara Nysom Christiansen Ole Rintek Madsen Mette Klarlund Marie Wetterslev Mate Lorincz Mads Bakkegaard Anne Duer Kasper Kjærulf Gosvig |
| author_facet | Merete Lund Hetland Inge Juul Sørensen Mikkel Østergaard Mikael Boesen Susanne Juhl Pedersen Sara Nysom Christiansen Ole Rintek Madsen Mette Klarlund Marie Wetterslev Mate Lorincz Mads Bakkegaard Anne Duer Kasper Kjærulf Gosvig |
| author_sort | Merete Lund Hetland |
| collection | DOAJ |
| description | Background The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) is a novel questionnaire of global functioning for patients with axial spondyloarthritis (SpA).Objective The objective was to assess the construct validity, discriminatory ability and responsiveness of ASAS HI in relation to patient-reported outcome measures (PROMs), MRI and radiography.Methods Data from two longitudinal studies with tumour necrosis factor inhibitor (TNFi) initiation (novel MRI And biomarkers in Golimumab-treated patients with axial spondyloarthritis (MANGO): n=45) respectively tapering (Dose adjustment of Biological treatment in patients with SpA (DOBIS): n=106) were used. Analyses included a wide panel of PROMs, MRI and radiography scores of the spine and sacroiliac joints (SIJs).Results In the MANGO study, 30 (68%) patients were clinical responders at week 16. In the DOBIS study, 105 (99%) patients flared after mean (SD; min–max) 31 (17; 2.7–81) weeks. After initiation of TNF inhibitor in MANGO, ASAS HI significantly decreased from baseline to week 4, 16 and 52. In DOBIS, ASAS significantly increased from baseline to the flare visit and significantly decreased from the flare visit to week 96. In multivariate regression models, ASAS HI was independently associated with Spondyloarthritis Research Consortium of Canada MRI SIJ Inflammation score, Canada-Denmark MRI Spine Inflammation score, EuroQol, Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Disease Activity Index and Patient Global. Patients stratified according to ASAS HI health status groups (good, moderate, poor) at baseline and change categories (absolute and percentage change) from baseline to week 16/flare showed good discriminatory ability for almost all outcome variables (p≤0.001). ASAS HI had a large responsiveness in MANGO (standardised response mean (SRM)=−1.3, effect size (ES)=−1.7) and moderate responsiveness in DOBIS (SRM=0.7, ES=0.6).Conclusion ASAS HI showed good construct validity, discriminatory ability and responsiveness.Trial registration number ClinicalTrials.gov: NCT02011386. |
| format | Article |
| id | doaj-art-aeb67ebed1514c1fb261f6b6804fd49d |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-aeb67ebed1514c1fb261f6b6804fd49d2025-01-14T20:25:08ZengBMJ Publishing GroupRMD Open2056-59332024-12-0110410.1136/rmdopen-2024-004948Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritisMerete Lund Hetland0Inge Juul Sørensen1Mikkel Østergaard2Mikael Boesen3Susanne Juhl Pedersen4Sara Nysom Christiansen5Ole Rintek Madsen6Mette Klarlund7Marie Wetterslev8Mate Lorincz9Mads Bakkegaard10Anne Duer11Kasper Kjærulf Gosvig12Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark3 Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark2 Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark6 Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark1 Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark3 Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark3 Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark3 Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark1 Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark1 Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark3 Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark5 Department of Radiology, Rigshospitalet Glostrup, Copenhagen, Denmark7 Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, DenmarkBackground The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) is a novel questionnaire of global functioning for patients with axial spondyloarthritis (SpA).Objective The objective was to assess the construct validity, discriminatory ability and responsiveness of ASAS HI in relation to patient-reported outcome measures (PROMs), MRI and radiography.Methods Data from two longitudinal studies with tumour necrosis factor inhibitor (TNFi) initiation (novel MRI And biomarkers in Golimumab-treated patients with axial spondyloarthritis (MANGO): n=45) respectively tapering (Dose adjustment of Biological treatment in patients with SpA (DOBIS): n=106) were used. Analyses included a wide panel of PROMs, MRI and radiography scores of the spine and sacroiliac joints (SIJs).Results In the MANGO study, 30 (68%) patients were clinical responders at week 16. In the DOBIS study, 105 (99%) patients flared after mean (SD; min–max) 31 (17; 2.7–81) weeks. After initiation of TNF inhibitor in MANGO, ASAS HI significantly decreased from baseline to week 4, 16 and 52. In DOBIS, ASAS significantly increased from baseline to the flare visit and significantly decreased from the flare visit to week 96. In multivariate regression models, ASAS HI was independently associated with Spondyloarthritis Research Consortium of Canada MRI SIJ Inflammation score, Canada-Denmark MRI Spine Inflammation score, EuroQol, Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Disease Activity Index and Patient Global. Patients stratified according to ASAS HI health status groups (good, moderate, poor) at baseline and change categories (absolute and percentage change) from baseline to week 16/flare showed good discriminatory ability for almost all outcome variables (p≤0.001). ASAS HI had a large responsiveness in MANGO (standardised response mean (SRM)=−1.3, effect size (ES)=−1.7) and moderate responsiveness in DOBIS (SRM=0.7, ES=0.6).Conclusion ASAS HI showed good construct validity, discriminatory ability and responsiveness.Trial registration number ClinicalTrials.gov: NCT02011386.https://rmdopen.bmj.com/content/10/4/e004948.full |
| spellingShingle | Merete Lund Hetland Inge Juul Sørensen Mikkel Østergaard Mikael Boesen Susanne Juhl Pedersen Sara Nysom Christiansen Ole Rintek Madsen Mette Klarlund Marie Wetterslev Mate Lorincz Mads Bakkegaard Anne Duer Kasper Kjærulf Gosvig Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis RMD Open |
| title | Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| title_full | Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| title_fullStr | Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| title_full_unstemmed | Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| title_short | Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| title_sort | construct validity and responsiveness of asas health index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis |
| url | https://rmdopen.bmj.com/content/10/4/e004948.full |
| work_keys_str_mv | AT meretelundhetland constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT ingejuulsørensen constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT mikkeløstergaard constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT mikaelboesen constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT susannejuhlpedersen constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT saranysomchristiansen constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT olerintekmadsen constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT metteklarlund constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT mariewetterslev constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT matelorincz constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT madsbakkegaard constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT anneduer constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis AT kasperkjærulfgosvig constructvalidityandresponsivenessofasashealthindexassessedintwolongitudinalstudiesoftumournecrosisfactoralphainhibitorinitiationanddosereductioninpatientswithaxialspondyloarthritis |